{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"82.40","upperLimit":"84.68","value":"83.54"},{"groupId":"OG001","lowerLimit":"86.42","upperLimit":"88.64","value":"87.53"}]}],"title":"Physical"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"77.14","upperLimit":"80.74","value":"78.94"},{"groupId":"OG001","lowerLimit":"83.70","upperLimit":"87.23","value":"85.46"}]}],"title":"Role"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"79.58","upperLimit":"82.27","value":"80.92"},{"groupId":"OG001","lowerLimit":"81.66","upperLimit":"84.29","value":"82.97"}]}],"title":"Emotional"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"84.17","upperLimit":"86.83","value":"85.50"},{"groupId":"OG001","lowerLimit":"86.13","upperLimit":"88.73","value":"87.43"}]}],"title":"Cognitive"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"79.04","upperLimit":"82.21","value":"80.62"},{"groupId":"OG001","lowerLimit":"86.44","upperLimit":"89.53","value":"87.99"}]}],"title":"Social"}],"denoms":[{"counts":[{"groupId":"OG000","value":"309"},{"groupId":"OG001","value":"306"}],"units":"Participants"}],"description":"Patient-reported outcomes (PROs) assessed health-related quality of life (QoL) by using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30), which was a 30-item questionnaire with global QoL scale \\& 5 multi-item functional scales (physical, role, emotional, cognitive, \\& social functioning). The questionnaire includes 28 items with 4-point Likert type responses from \"not at all\" to \"very much\" to assess functioning; 2 items with 7-point Likert scales for global health \\& overall QoL. All responses were converted to a 0 to 100 scale using a standard scoring algorithm, higher scores represented better level for functioning/QoL.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received Sunitinib on 9 6-week cycles on 4/2 dosing schedule: 4 weeks on, 2 weeks off.","id":"OG000","title":"Sunitinib"},{"description":"Participants received Placebo on 9 6-week cycles with 4/2 dosing schedule: 4 weeks on, 2 weeks off.","id":"OG001","title":"Placebo"}],"paramType":"MEAN","populationDescription":"ITT population included all participants who were randomized, with study drug assignment designated according to initial randomization, regardless of whether participants received study drug or received a different drug from that to which they were randomized.","reportingStatus":"POSTED","timeFrame":"Cycle 1(Day 1); subsequent cycles (Day 1) and end of treatment/withdrawal (ie, up to 1 year)","title":"PROs- EORTC QLQ C30: Functional Scale Scores Between Treatment Comparison","type":"SECONDARY","unitOfMeasure":"Scores on scale"}